Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy

Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy The Guardian Veracyte genomic test identifies breast cancer patients who can skip chemo Reuters Genetic test could offer breast cancer patients chance to skip chemo The Times Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy Business Wire OPTIMA Phase III: Gene Expression Test Helps Identify Patients Who May Avoid Chemotherapy Docwire News